Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersanaâs lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersanaâs platform to advance their ADC pipelines. Source
No articles found.
We are a network of full-service medical equipment companies that use tailored pro...
We are a network of full-service medical equipm...
Maternova, Inc. is the trusted resource for cutting edge medical innovations in ne...
Maternova, Inc. is the trusted resource for cut...
argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...
argenx is a clinical-stage biotechnology compan...
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
Join the National Investor Network and get the latest information with your interests in mind.